Keuer Thomas A
Known title: Chief Operating OfficerCIK: 0001290482
Associated companies
Transaction History
| ORKA | ▲ Buy | Grant | 40,000 | $0 | 12/8/2022 | View on chart |
| ORKA | ▲ Buy | Grant | 40,000 | $0 | 12/8/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
HC Wainwright Reiterates $120 Target on Oruka
HC Wainwright maintained its buy rating on Oruka Therapeutics, keeping its price target at $120. The firm continues to see the company favorably despite recent trading levels well below that target. The analyst consensus average for the stock stands at $153.75, with estimates ranging from $102 to $200.
HC Wainwright Reiterates $120 Target on Oruka. HC Wainwright maintained its buy rating on Oruka Therapeutics, keeping its price target at $120. The firm continues to see the company favorably despite recent trading levels well below that target. The analyst consensus average for the stock stands at $153.75, with estimates ranging from $102 to $200.